Global Connected / Smart Drug Delivery Systems Market Report 2021: Current Landscape and Future Outlook for Devices Already Commercialized or Under Development

News provided by

May 11, 2021, 10:45 ET

DUBLIN, May 11, 2021 /PRNewswire/ -- The "Connected / Smart Drug Delivery Systems Market by Product Type, Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions: Industry Trends and Global Forecasts 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The report features an extensive study of the current landscape and future outlook of the growing market for connected drug delivery devices that are either already commercialized or are under development.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in mid to long-term, for the period 2020-2030.

Our year-wise projections of the current and future opportunity have further been segmented on the basis of:

Type of solution (connected drug delivery devices and add-on sensors)
Type of product (connected inhalers, connected handheld injectors and connected wearable injectors)
Therapeutic areas (metabolic disorders, neurological disorders, respiratory disorders, and others)
Route of administration (injectable and inhalable)
Key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

To account for the uncertainties associated with the development of these connected drug delivery devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Amongst other elements, the report features:

A detailed assessment of the current market landscape of more than 65 connected drug delivery devices based on a number of relevant parameters such as
Type of device, namely connected inhalers, connected handheld injectors (connected pen injectors, connected autoinjectors and connected needle-free injectors) and connected wearable injectors (connected insulin pumps and connected patch pumps)
Status of development (approved / launched or under development)
Mode of drug delivery (injectable, inhalation and oral)
Targeted therapeutic area (metabolic disorders, respiratory disorders, neurological disorders, hormonal disorders and others)
Type of connectivity solution offered,
Other key device specifications (audio / visual reminders, connectivity, companion mobile applications, companion web portal, data storage / cloud platform options, rechargeable batteries / battery backup and reminder / notifications / alerts).

Key Questions Answered

Who are the leading developers of connected / smart drug delivery systems?
What are the popular types of drug delivery devices that are currently being marketed / developed in this domain?
What are the novel / advanced features that device developers are incorporating in their respective devices, to maintain a competitive edge in the market?
What is the relative competitiveness of different connected solutions across several device segments?
What kind of partnership models are commonly being adopted by stakeholders in this industry?
What is the trend in capital investments in the connected drug delivery device market?
What is the overall cost distribution across the value chain of connected drug delivery devices?
What is the impact of COVID-19 outbreak on connected drug delivery devices market?
What are the factors that are likely to influence the evolution of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to connected drug delivery devices market?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Connected / Smart Drug Delivery Systems: Market Landscape

5. Add-On Sensors: Market Landscape

6. Product Competitiveness Analysis

7. Company Profiles

8. Clinical Trial Analysis

9. Partnerships And Collaborations

10. Funding And Investment Analysis

11. Value Chain / Cost Price Analysis

12. Market Forecast And Opportunity Analysis

13. Impact Of Covid-19 Pandemic On The Connected Drug Delivery Devices Market

14. Regulatory Landscape

15. Case Study

16. SWOT Analysis

17. Concluding Remarks

18. Executive Insights

19. Appendix 1: Tabulated Data

COMPANY PROFILES

Company Profiles
BIOCORP
Elcam Drug Delivery Devices (E3D)
Novo Nordisk
Merck
Pneuma Respiratory
H&T Presspart
Nemera

Companies Mentioned

3E Bioventures Capital
3M
5AM Ventures
A. Menarini Diagnostics
Abbott
Academic Pediatric Association
Adherium
Adocia
Aerobit Health
AgaMatrix
Aguettant
AIRBRIO
Airnest
Allegheny Health Network
AMC Health
Amiko
Andaluz Health Service
Anthem Blue Cross and Blue Shield
Apellis Pharmaceuticals
Aptar Pharma
Aristotle University of Thessaloniki
ARTORG Center
Asante Solutions
Asthma and Respiratory Foundation NZ
AstraZeneca
Australasian Medical & Scientific
Bank of China Group Investment
Barbara Davis Center
Bayer
Becton Dickinson
Bigfoot Biomedical
BioAdvance
BIOCORP
BioScience Managers
Black Pearls
Blackstone Life Sciences
Blue Cross and Blue Shield
Boehringer Ingelheim
Robert Bosch Venture Capital
Bosman Medical Devices
Boston Children's Hospital
Breed Reply
Calgary Health Trust
Cam Med
Cambridge Consultants
Cambridge University Hospitals
Capital Royalty Partners II
Centre Hospitalier de Luxembourg
Chengdu Municipal Government
Children's Hospital of Philadelphia
Christchurch Clinical Studies Trust
Chronicare
Cincinnati Children's Hospital
CincyTech
Cintrifuse
Cleveland Clinic
Cognita Labs
Cohero Health
Common Sensing
Companion Medical
Connecticut Children's Medical Center
Cormorant Asset Management
Crux Product Design
Debiotech
Desert Oasis Healthcare
Dexcom
Diabeloop
Diabnext
DreaMed Diabetes
E3D Elcam Drug Delivery Devices
Eli Lilly
EMD Serono
Emory University
Emperra
Enable Injections
EOFlow
etectRx
Eularis
International Diabetes Federation
Express Scripts
Fenway Health
Fidelity International
FindAir
Fitbit
Flex Digital Health
Gecko Health (acquired by Teva Pharmaceuticals)
Genentech
Gerresheimer
Gilead Sciences
GIS Strategic Ventures
Glooko
Gloria Pharmaceuticals
GlucoRx
GSK
H&T Presspart
Haisco Pharmaceutical
Hamad Medical
Harvard University
Haselmeier
Health Innovations
Health2Sync
HealthPartners Institute
HealthPrize Technologies
Heitkamp & Thumann Group
HGE Health
Hikma Ventures
Hoffmann-La Roche
HP Labs
Huons
IBM
Idea Bridge
ImagineCare
Imperial College London
Indiana University
INKEF Capital
Innovation Zed
Institut de Recherches Cliniques de Montreal
Insulclock
Insulcoud S.L.
Insulet
International Clinical Trials Association
International Diabetes Center at Park Nicollet
Investitionsbank des Landes Brandenburg
Invest-NL
iSage Rx
i-SENS
iSense
Ismanis Engineering
Jaeb Center for Health Research
Janus Henderson
JDRF T1D Fund
Joslin Diabetes Center
Juvenile Diabetes Research Foundation
K2 HealthVentures
Kali Care
Kap Code
K-Bio Health
Klue
Kreos Capital
LB Investment
Leads Biolabs
Legacy Health
LEO Pharma
Life Sciences Partners
LINDAL Group
Lupin
Luz Saude
The University of Manchester
McKesson Ventures
MedCrypt
Medical International Research
Medical Research Institute of New Zealand
Medical University of Graz
Medical University of South Carolina
Medtronic
Medtrum
Merck KGaA
MidMichigan Health
Mode
Molina Healthcare
Monaghan Medical Corporation
Morningside Venture Capital
Mountain Diabetes and Endocrine Center
Movi
mySugr
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health
National Library of Medicine (NLM)
Navia Life Care
Nemera
Nemours
New World Health
New Zealand Medical & Scientific
nGageIT Digital Health Solutions
NHS Foundation Trust
Noble International
Nordic Infucare
Northwestern University
Norton Healthcare
Novartis
Novo Nordisk
National Science Foundation
Nutrino Health (acquired by Medtronic)
Ohio Innovation Fund
OMRON Healthcare
One Drop
One Funds Management
Oregon Health and Science University
ORI Healthcare Fund
Orion
Otsuka Pharmaceutical
Owen Mumford
Owsley Brown Charitable Foundation
P5 Health Ventures
Patients Know Best
Pendiq
Peppermint VenturePartners
PercuSense
PharmaSens
Planet Innovation
Pneuma Respiratory
Portal Instruments
ProCare
Propeller Health
Proteus Digital Health
Quadrant Capital Advisors
Qualcomm
Qualicaps
QuiO
Quotient Sciences
Rabin Medical Center
Reciprocal Labs
ResMed
Respia
Rimidi
Roche
Philips
Rubin Medical
Safeguard Scientifics
Sagentia
Samsung
Sanner
Sanofi
Sansum Diabetes Research Institute
Schneider Children's Medical Center
Senseonics
Sensile Medical
Senvest Capital
Sequoia Capital China
SFC Fluidics
SHL Medical
Sidra Medicine
Sirma Medical Systems
Smartgateways
Smile
Sonceboz
Sonmol
SOOIL Development
Sorrel Medical
SQ Innovation
SR One
Stanford University
Stevanato Group
Summatix
Sunrise Labs
Swanhill Capital
Syneos Health
T1D Exchange
Takeda Pharmaceutical
Tandem Diabetes Care
Teva Pharmaceuticals
Texas Diabetes & Endocrinology
The Leeds Teaching Hospitals
Massachusetts Life Sciences Center (MLSC)
Thea Group
Theras
Three Leaf Ventures
Tidepool
Timesulin
Trade Capital Funding
Trudell Medical
TypeZero Technologies (acquired by Dexcom)
UCB
UnitedHealth
Grenoble Alpes University Hospital
University of Alabama
University of Calgary
University of California
University of Cambridge
University of Colorado
University of Edinburgh
University of Florida
University of Ljubljana
University of Minnesota
University of Padova
University of Pennsylvania
University of Virginia
Vatel Capital
Vectura Group
Verily
ViCentra
Visionnaire Ventures
Vitalus Health
Waterline Ventures
Welkin Health
West Pharmaceutical Services
Xeris Pharmaceuticals
Yale University
Ypsomed
Zaffre Investments
Zealand Pharma
Zhangjiang Venture Investment

For more information about this report visit https://www.researchandmarkets.com/r/288f0a

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets